The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma
Abstract
OBJECTIVES: Phaeochromocytoma may be either sporadic or part of a familial cancer syndrome. We have investigated whether there are differences between sporadic and MEN 2A phaeochromocytomas. DESIGN: A retrospective study. We analysed age at presentation, sex, mode of presentation, clinical data, laboratory and imaging techniques, treatment, pathology and follow-up. PATIENTS: Forty-six patients diagnosed with phaeochromocytoma between 1979 and 1995 (23 sporadic and 23 familial) at the Hospital Universitario Virgen de la Arrixaca (Murcia, Spain), a tertiary referral centre. RESULTS: Mean age at presentation was 47 +/- 16 years for sporadic and 38 +/- 11 years for familial phaeochromocytoma (P < 0.05). The most common clinical feature and the presenting feature in cases of isolated phaeochromocytoma was hypertension. Of the MEN 2A patients, 52% were asymptomatic at diagnosis and only 35% presented with hypertension. Levels of adrenaline, noradrenaline, dopamine and metanephrines in a 24-hour urine connection confirmed the diagnosis in 95% of the isolated and 91% of the familial phaeochromocytomas. Computed tomography located 100% of the sporadic and 76% of the familial phaeochromocytomas (P < 0.02). All the MEN 2A phaeochromocytomas were bilateral compared with none of the sporadic phaeochromocytomas (P < 0.001). All the patients with familial phaeochromocytoma underwent bilateral adrenalectomy. The patients with sporadic phaeochromocytoma had the affected gland or the tumour, if extraadrenal, removed. CONCLUSIONS: In comparing sporadic and MEN 2A phaeochromocytoma we found differences in age at presentation, mode of presentation, clinical data, duration of clinical features, imaging findings bilaterality and type of surgical treatment required.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Patients with familial pheochromocytoma may be asymptomatic in 50% of cases, with only a third presenting with hypertension.
“Patients with familial pheochromocytoma may be asymptomatic in 50% of cases, with only a third presenting with hypertension, possibly representing earlier diagnosis and smaller lesions as a result of regular screening in these patients (195,196).”
From Adrenal incidentaloma (2020) · cites this paper as [195]
Citations
Cites
The n e w e n g l a n d j o u r n a l of m e d i c i n e
Gelijns, A., Rosenberg, N., & Moskowitz, A. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm192802231980115 · Cited by 7,286
(2019) · Journal of Human Hypertension · doi:10.1038/41371.1476-5527 · Cited by 389
TheRETProto-Oncogene in Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease
Eng, C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609263351307 · Cited by 330
Plasma Metanephrines in the Diagnosis of Pheochromocytoma
Lenders, J. W. M., Keiser, H. R., Goldstein, D. S., Willemsen, J. J., Friberg, P., Jacobs, M.-C., Kloppenborg, P. W. C., Thien, T., & Eisenhofer, G. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-2-199507150-00004 · Cited by 242
Management of Pheochromocytomas in Patients with Multiple Endocrine Neoplasia Type 2 Syndromes
Lairmore, T. C., Ball, D. W., Baylin, S. B., & Wells, S. A. (1993) · Annals of Surgery · doi:10.1097/00000658-199306000-00001 · Cited by 214
Recent Developments in the Diagnosis and Treatment of Pheochromocytoma
Sheps, S. G., Jiang, N., Klee, G. G., et al. (1990) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)62113-2 · Cited by 177
Howe, J. R., Norton, J. A., & Wells, S. A. (1993) · PubMed · Cited by 176
Pheochromocytoma in multiple endocrine neoplasia type 2: European study
Modigliani, E., Vasen, H. F. A., Raue, K. D., et al. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb01211.x · Cited by 172
Pheochromocytoma: Update on Diagnosis, Localization, and Management
Werbel, S. S., & Ober, K. P. (1995) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30088-8 · Cited by 165
Multiple Endocrine Neoplasia Type 2: Clinical Features and Screening
Raue, F., Frank‐Raue, K., & Grauer, A. (1994) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30121-x · Cited by 127
Pheochromocytoma--continuing evolution of surgical therapy.
Orchard, T. J., Grant, C. S., van Heerden, J. A., et al. (1993) · PubMed · Cited by 110
Phaeochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 cases
Casanova, S., Rosenberg‐Bourgin, M., Farkast, D., et al. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb00350.x · Cited by 98
Phaeochromocytoma and paraganglioma
Fonseca, V. A., & Bouloux, P.-M. G. (1993) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80186-7 · Cited by 84
Lips, K. J. M., Veer, J. V. D. S., Struyvenberg, A., Alleman, A., Leo, J. R., WITTEBOL, P., Minder, W. H., Kooiker, C. J., Geerdink, R. A., van Waes, P. F. G. M., et al. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90866-4 · Cited by 79
Pheochromocytoma: current diagnosis and management
Vidt, D. G., Bakst, A., Manger, W. M., et al. (1993) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.60.5.365 · Cited by 71
Laboratory Diagnosis of Phaeochromocytoma: Which Analytes Should We Measure?
Graham, P. E., Smythe, G. A., Edwards, G., & Lazarus, L. (1993) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456329303000203 · Cited by 70
A-I-D-S: the new endocrine epidemic.
Griffing, G. T. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989451 · Cited by 65
Adrenal Medullary Disease in Multiple Endocrine Neoplasia Type 2: Appropriate Management
Evans, D. B., Lee, J. E., Merrell, R. C., et al. (1994) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30123-3 · Cited by 55
Biochemical detection of phaeochromocytoma: should we still be measuring urinary HMMA?
Peaston, R., & Lai, L. C. (1993) · Journal of Clinical Pathology · doi:10.1136/jcp.46.8.734 · Cited by 40
Pediatric malignant pheochromocytoma
Ein, S. H., Weitzman, S. S., Thorner, P. S., et al. (1994) · Journal of Pediatric Surgery · doi:10.1016/0022-3468(94)90799-4 · Cited by 36
A-I-D-S: the new endocrine epidemic
Griffing, G. T. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.79.6.1530 · Cited by 34
Imaging of catecholamine-secretion tumours: uses of MIBG in diagnosis and treatment
Shapiro, B. (1993) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80185-5 · Cited by 30
Endocrinology and Metabolism Clinics of North America
(2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(20)30051-7 · Cited by 29
131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma
Sakahara, H., Endo, K., Saga, T., et al. (1994) · Annals of Nuclear Medicine · doi:10.1007/bf03165018 · Cited by 23
Endocrine crises. Pheochromocytoma.
Shapiro, B., & Gross, M. D. (1991) · PubMed · Cited by 15
Meta-iodobenzylguanidine (MIBG) scanning in the diagnosis of phaeochromocytoma.
Cj, C., Kennedy, A., Jp, L., et al. (1993) · PubMed · Cited by 10
Familial neuroendocrine tumors as a model of hereditary cancer
Anderson, R. J., & Lynch, H. T. (1997) · Current Opinion in Oncology · doi:10.1097/00001622-199701000-00008 · Cited by 4
Flagged first, then by citations
Research works printed but not linked: 6
- Bravo E.L., 1984, New England Journal of Medicine, 30, 1682
- Bravo E.L., 1993, Endocrinology and Metabolism Clinics of North America, 22, 329
- Howe J.R., 1993, Surgery, 114, 1070
- Orchard T., 1993, Surgery, 114, 1153
- Raue F., 1994, Endocrinology and Metabolism Clinics of North America, 23, 137
- Shapiro B., 1991, Critical Care Clinics, 7, 1
Cited by
Sorted by citations
Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma
Pacak, K., Linehan, W. M., Eisenhofer, G., Walther, M. M., & Goldstein, D. S. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-4-200102200-00016 · Cited by 618
Sleep Restriction for 1 Week Reduces Insulin Sensitivity in Healthy Men
Buxton, O. M., Pavlova, M., Reid, E. W., Wang, W., Simonson, D. C., & Adler, G. K. (2010) · Diabetes · doi:10.2337/db09-0699 · Cited by 604
Sherlock, M., Scarsbrook, A., Abbas, A., Fraser, S., Limumpornpetch, P., Dineen, R., & Stewart, P. M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa008 · Cited by 347
WALTHER, M. M., REITER, R., KEISER, H. R., CHOYKE, P. L., VENZON, D., HURLEY, K., GNARRA, J. R., REYNOLDS, J. C., GLENN, G. M., ZBAR, B., et al. (1999) · Journal of Urology · doi:10.1097/00005392-199909010-00004 · Cited by 255
Pheochromocytoma: The expanding genetic differential diagnosis.
Bryant, J., Farmer, J., Kessler, L. J., Townsend, R. R., & Nathanson, K. L. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg024 · Cited by 250
Metadata
- Authors
- Pomares, F. J., Canas, R., Rodriguez, J. M., Hernandez, A. M., Parrilla, P., & Tebar, F. J.
- Affiliations
- Hospital Universitario Virgen de la Arrixaca (ES)
- ORCID
- Pomares, F. J.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 1998-02
- Volume
- 48
- Issue
- 2
- Pages
- 195-200
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2095363025
- Cited by
- 124
- References
- 27
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 4 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 7 · 2015: 3 · 2014: 6 · 2013: 4 · 2012: 6
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- pheochromocytoma, multiple endocrine neoplasia type 2A, hereditary cancer, age at presentation, hypertension, adrenalectomy, surgical treatment, tumor imaging
- MeSH terms
- Adolescent, Adrenal Gland Neoplasms, Adrenalectomy, Adult, Aged, Child, Diagnosis, Differential, Dopamine, Epinephrine, Female, Humans, Hypertension, Male, Metanephrine, Middle Aged, Norepinephrine, Pheochromocytoma, Retrospective Studies, Tomography, X-Ray Computed, Age of Onset, Multiple Endocrine Neoplasia Type 2a
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review